Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 81

Sort by

Sort Order Select

Journal Articles

Transcriptomic Analysis of αCD19 CAR T Cells Reveals Venetoclax-Induced Changes in T Cell Quality and Function

Taylor K Mandeville, Jacob P Wright, Cory Mavis, Matthew J. Cortese, MD, MPH, Spencer Rosario, Scott Olejniczak, Francisco Hernandez-Ilizaliturri

Blood (2024) 144 (Supplement 1): 1036.

https://doi.org/10.1182/blood-2024-212101

Published: 2024

Journal Articles

Multiomic Evaluation of Immunologic Changes in Chronic Lymphocytic Leukemia with Venetoclax Treatment

Matthew J. Cortese, MD, MPH, Jacob P Wright, Cory Mavis, Taylor K Mandeville, Alex Niu, Dae-Kyum Kim, Spencer Rosario, Francisco Hernandez-Ilizaliturri

Blood (2024) 144 (Supplement 1): 78.

https://doi.org/10.1182/blood-2024-212019

Published: 2024

Journal Articles

Evasion of αCD19 CAR T-Mediated Killing By Rituximab-Chemotherapy Resistant Lymphoma Cells

Taylor K Mandeville, Jacob P Wright, Cory Mavis, Matthew J. Cortese, MD, MPH, Spencer Rosario, Scott Olejniczak, Francisco Hernandez-Ilizaliturri

Blood (2024) 144 (Supplement 1): 5762.

https://doi.org/10.1182/blood-2024-212215

Published: 2024

Journal Articles

Venetoclax Pre-Treatment of CLL/SLL Patients Enhances Autologous CAR T-Cells Efficacy

Matthew J Cortese, Cory Mavis, Taylor K Mandeville, Juan Gu, Kevin Bowman, Francisco J. Hernandez-Ilizaliturri

Blood (2023) 142 (Supplement 1): 6518.

https://doi.org/10.1182/blood-2023-189733

Published: 2023

Journal Articles

Compatibility of Venetoclax and OPN51107 in Treatment of Mantle Cell Lymphoma

Kevin Bowman, Cory Mavis, Juan Gu, Taylor K Mandeville, Jessica C Wang, Matthew J Cortese, Francisco J. Hernandez-Ilizaliturri

Blood (2023) 142 (Supplement 1): 6102.

https://doi.org/10.1182/blood-2023-189739

Published: 2023

Journal Articles

Mitochondrial Reprogramming By Bcl-2 Inhibitor Venetoclax Enhances αCD19 CAR-T Cell Fitness and Anti-Tumor Efficacy

Taylor K Mandeville, Cory Mavis, Juan Gu, Kevin Bowman, Scott Olejniczak, Prasenjit Dey, Gyorgy Paragh, Matthew J Cortese, Francisco J. Hernandez-Ilizaliturri

Blood (2023) 142 (Supplement 1): 6845.

https://doi.org/10.1182/blood-2023-191051

Published: 2023

Journal Articles

Novel Drug to Target HK2 Overcomes Therapeutic Resistance in Preclinical B-Cell Lymphoma Models

Juan Gu, Cory Mavis, Jessica C Wang, Kevin Bowman, Taylor K Mandeville, Ahmet E Tatar, Zepnep Benekli, Matthew J Cortese, Francisco J. Hernandez-Ilizaliturri

Blood (2023) 142 (Supplement 1): 5793.

https://doi.org/10.1182/blood-2023-185189

Published: 2023

Journal Articles

PLX51107 Enhances the Anti-Tumor Activity of Targeted Therapy in Chronic Lymphocytic Leukemia When Combined with Venetoclax

Cory Mavis, Kevin Zablonski, Suchitra Sundaram, Juan Gu, Pallawi Torka, Francisco Hernandez-Ilizaliturri

Blood (2022) 140 (Supplement 1): 12357–12358.

https://doi.org/10.1182/blood-2022-169123

Published: 2022

Journal Articles

Effect of Mcl-1 Inhibitor, AMG-176, on T Cell Quality and Function

Noah Lemoine, Taylor K Mandeville, Cory Mavis, Kevin Bowman, Juan J. Gu, Francisco Hernandez-Ilizaliturri

Blood (2022) 140 (Supplement 1): 12706–12707.

https://doi.org/10.1182/blood-2022-170122

Published: 2022

Journal Articles

Enhancing α-CD19 CAR T Antitumor Efficacy Using the BH3 Mimetic, Venetoclax

Taylor Mandeville, Cory Mavis, Juan Gu, Noah Lemoine, Kevin Bowman, Scott Olejniczak, Prasenjit Dey, Gyorgy Paragh, Francisco Hernandez-Ilizaliturri

Blood (2022) 140 (Supplement 1): 7398–7399.

https://doi.org/10.1182/blood-2022-170436

Published: 2022

Journal Articles

Targeting BCL-XL to Overcome Anti-CD20 Antibodies and Venetoclax Resistance in Pre-Clinical Model of Diffuse Large B Cell Lymphoma

Juan J. Gu, Jessica Wang, Cory Mavis, Taylor K Mandeville, Pallawi Torka, Francisco Hernandez-Ilizaliturri

Blood (2022) 140 (Supplement 1): 11562–11563.

https://doi.org/10.1182/blood-2022-159120

Published: 2022

Journal Articles

Enhanced Anti-Tumor Activity with Exposure to BCL-2 and BRD4 Inhibitors in Mantle Cell Lymphoma

Kevin Bowman, Cory Mavis, Taylor K Mandeville, Noah Lemoine, Juan Gu, Francisco Hernandez-Ilizaliturri

Blood (2022) 140 (Supplement 1): 8850.

https://doi.org/10.1182/blood-2022-169438

Published: 2022

Journal Articles

Soluble ICAM-1 As Effective Serologic Marker to Predict Clinical Outcome for Early -Stage I/II Nasal Natural Killer /T-Cell Lymphoma

Juan J Gu, Paola Ghione, Shiyu Jiang, Cory Mavis, Francisco J. Hernandez-Ilizaliturri, Dongmei Ji, Junning Cao, Xiaonan Hong, Xuejun Ma, Qunling Zhang

Blood (2021) 138 (Supplement 1): 4542.

https://doi.org/10.1182/blood-2021-149229

Published: 2021

Journal Articles

Contribution of Bcl-2 Inhibitor Venetoclax Toward Anti-CD19 CAR T Cell Efficacy in Relapsed/Refractory Diffuse Large B Cell Lymphoma

Taylor K Mandeville, Cory Mavis, Juan Gu, Scott Olejniczak, Gyorgy Paragh, Prasenjit Dey, Francisco J. Hernandez-Ilizaliturri

Blood (2021) 138 (Supplement 1): 1719.

https://doi.org/10.1182/blood-2021-154128

Published: 2021

Journal Articles

Determinants of COVID-19 Vaccine Response in Patients with Lymphoma on B Cell Directed Therapy

Shipra Goel, Juan J. Gu, Pallawi Torka, Cory Mavis, Suchitra Sundaram, Mirdza Neiders, Lakshmanan Suresh, Long Shen, Vince Ramsperger, Elizabeth A. Griffiths, Brahm Segal, Francisco J. Hernandez-Ilizaliturri, Paola Ghione

Blood (2021) 138 (Supplement 1): 1340.

https://doi.org/10.1182/blood-2021-152738

Published: 2021

Journal Articles

Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell–directed therapies

Blood (2021) 138 (9): 811–814.

https://doi.org/10.1182/blood.2021012443

Published: 2021

Includes: Supplemental data

Journal Articles

BRD4 Inhibitors Enhance the Anti-Tumor Activity of Targeted Therapy in Chronic Lymphocytic Leukemia

Suchitra Sundaram, MD, Cory Mavis, MSc, Juan J Gu, PhD, Pallawi Torka, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2020) 136 (Supplement 1): 37.

https://doi.org/10.1182/blood-2020-143237

Published: 2020

Journal Articles

Potentiate Immune Activation and Function By Targeting Inhibitor of Apoptosis Proteins (IAPs) in Relapse/Refractory DLBCL

Juan J Gu, MD PhD, Cory Mavis, MSc, Pallawi Torka, MD, Suchitra Sundaram, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-137812

Published: 2020

Journal Articles

Ofatumumab Plus Hypercvad/MA Induction Leads to High Rates of Minimal Residual Disease (MRD) Negativity in Patients with Newly Diagnosed Mantle Cell Lymphoma, Results of a Phase 2 Study

Pallawi Torka, MD, Nishitha Reddy, MD, Adrienne Groman, MS, Angela Kader, Jenna Nichols, Alan Hutson, Cory Mavis, MSc, Joseph Dennis Tario, PhD, Paul K. Wallace, MS, PhD, AnneMarie W. Block, PhD, Sheila N. J. Sait, PhD, Bora E Baysal, MD PhD, Vishala T. Neppalli, MD, Suchitra Sundaram, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2019) 134 (Supplement_1): 2817.

https://doi.org/10.1182/blood-2019-123488

Published: 2019

Journal Articles

Targeting MDM2 and XIAP By Idasanutlin in Diffuse Large B-Cell Lymphoma

Juan J. Gu, MD PhD, Samuel J. Thompson, Cory Mavis, MSc, Matthew J. Barth, MD, Pallawi Torka, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2019) 134 (Supplement_1): 5301.

https://doi.org/10.1182/blood-2019-129009

Published: 2019

NARROW

Transcriptomic Analysis of αCD19 CAR T Cells Reveals Venetoclax-Induced Changes in T Cell Quality and Function

Multiomic Evaluation of Immunologic Changes in Chronic Lymphocytic Leukemia with Venetoclax Treatment

Evasion of αCD19 CAR T-Mediated Killing By Rituximab-Chemotherapy Resistant Lymphoma Cells

Venetoclax Pre-Treatment of CLL/SLL Patients Enhances Autologous CAR T-Cells Efficacy

Compatibility of Venetoclax and OPN51107 in Treatment of Mantle Cell Lymphoma

Mitochondrial Reprogramming By Bcl-2 Inhibitor Venetoclax Enhances αCD19 CAR-T Cell Fitness and Anti-Tumor Efficacy

Novel Drug to Target HK2 Overcomes Therapeutic Resistance in Preclinical B-Cell Lymphoma Models

PLX51107 Enhances the Anti-Tumor Activity of Targeted Therapy in Chronic Lymphocytic Leukemia When Combined with Venetoclax

Effect of Mcl-1 Inhibitor, AMG-176, on T Cell Quality and Function

Enhancing α-CD19 CAR T Antitumor Efficacy Using the BH3 Mimetic, Venetoclax

Targeting BCL-XL to Overcome Anti-CD20 Antibodies and Venetoclax Resistance in Pre-Clinical Model of Diffuse Large B Cell Lymphoma

Enhanced Anti-Tumor Activity with Exposure to BCL-2 and BRD4 Inhibitors in Mantle Cell Lymphoma

Soluble ICAM-1 As Effective Serologic Marker to Predict Clinical Outcome for Early -Stage I/II Nasal Natural Killer /T-Cell Lymphoma

Contribution of Bcl-2 Inhibitor Venetoclax Toward Anti-CD19 CAR T Cell Efficacy in Relapsed/Refractory Diffuse Large B Cell Lymphoma

Determinants of COVID-19 Vaccine Response in Patients with Lymphoma on B Cell Directed Therapy

Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell–directed therapies

BRD4 Inhibitors Enhance the Anti-Tumor Activity of Targeted Therapy in Chronic Lymphocytic Leukemia

Potentiate Immune Activation and Function By Targeting Inhibitor of Apoptosis Proteins (IAPs) in Relapse/Refractory DLBCL

Ofatumumab Plus Hypercvad/MA Induction Leads to High Rates of Minimal Residual Disease (MRD) Negativity in Patients with Newly Diagnosed Mantle Cell Lymphoma, Results of a Phase 2 Study

Targeting MDM2 and XIAP By Idasanutlin in Diffuse Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only